In summary, these data suggest that MARK4 deficiency can improve the abnormal lipid metabolism of cardiomyocytes induced by DCM, promote the oxidative breakdown of lipids, and reduce the myocardial accumulation of lipids. This evidence concerns the gene MARK4 and familial dilated cardiomyopathy.